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Abstract
ENANTIOMERIC INFLUENCES IN NEUROLEPTIC BINDING TO
MODELS OF THE DOPAMINE RECEPTOR
by
Timothy A. Robert
Various in vitro models are believed to represent a
physiologically relevant dopaminergic component of schizo
phrenia. Neuroleptic agents competitively inhibit both
dopamine-sensitive adenylate cyclase (DA/AC) and radiolabeled
agonist or antagonist binding In neuronal homogenates.
The
effects of a few dopamine antagonists have been shown to be
stereospecific in vivo and in vitro. Experiments were under
taken to further examine the in vitro dopaminergic effects
of optically active phenothiazTne derivatives.
Such studies
were also intended to help clarify the relationship between
DA/AC, 3H-dopamine binding (3H-DA), and 3H-spiroperidol.
(3H-SP) binding.
Binding studies were performed in calf caudate nucleus
homogenates with (+) and (-) methotrimeprazine, (+) and (-)
thioridazine, (+) and (+) promethazine, (+) and (-) dioxopromethazine, and (+) and (-) P-892. Various concentrations
were examined for their ability to compete with 5nM 3H~DA or
0.15nM 3H-SP binding.
In addition, (+) and (-) methotrimeprazine isomers were evaluated in the DA/AC assay. Rat caud
ate nuclei were pooled and homogenized in the studies of
methotrimeprazine inhibition of DA/AC cyclic adenosine 3',5*
monophosphate (cAMP) production. Enzyme activity was esti
mated by measuring, via radioimmunoassay, pmol cAMP produced/
mg protein/minute.
It was observed that there was a significant (P<0.05,
analysis of variance) isomeric effect only for the neuro
leptics, thioridazine and methotrimeprazine, in displacing
3H-DA wheras 3H-SP competition exhibited stereospecificity
with promethazine and dioxoproraethazine as well.
Isomer
pairs differed in their magnitudes of stereospecificity
(ratio of 50% inhibitory concentrations of (+) and (-) iso
mers) between 3H-DA and 3H-SP displacement.
In marked con
trast to the radioligand binding results, DA/AC failed to
exhibit an isomeric effect upon inhibition with methotrimep
razine.
These observations suggest that the binding sites for
dopamine agonists and antagonists associated with these in
vitro models are all different molecular species.
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PREFACE
The necessary counterpart of any neurotransmitter is its
receptor located upon the target cell.

Receptors themselves

are responsible for transduction of the chemical message to
an initial physiological effect.

Many theoretical models of

receptors have been proposed (Triggle, '78) over the years
to account for the observed effects of transmitters and drugs
upon their receptive structures.

A theory developed by

A.J. Clark early in the 1920's remains the cornerstone of
receptor models.

While the features of various models such

as occupation theory, receptor reserve, or rate theory may be
different, there remains the common element of drug/receptor
interaction.

An essential first step in this process is the

recognition between chemical mediator and the receptive
structure.

This biochemical interaction is fundamentally

determined by structural compatability of the transmitter and
its recognition site.

The process of recognition is based

upon chemical and stereochemical parameters which are crucial
determinants of both transmitter and drug action at the
molecular level.

Stereoisomers of efficacious agents with

even the most subtle differences in configuration are
differentiable by their receptors.

It was the purpose of the

experiments described herein to examine the stereospecificity
of antagonistic molecular interactions with a representative
central nervous system dopamine receptor.
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I.

A.

INTRODUCTION

In Vivo Studies
The compound, 3 ,4-dihydroxyphenylethylamine, commonly

referred Co as dopamine (DA), has been Implicated as a
neurotransmitter in diverse tissues in many species (Cooper
et a l . , '74; Goldberg et^ a l ., *78).

In peripheral tissues

of higher animals, this compound is not found alone in
their innervating neurons (Horn,

*75).

Indeed, the

mechanism of specific dopaminergic actions in renal, mesen
teric, coronary, and cerebral vascular beds may be con
founded by interactions with other adrenergic receptors.
The renal preparation studied by Goldberg et.al..('78) is
suggestive of significant differences between these peri
pheral receptors and others such as those in the central
nervous system (CNS).
It is possible that DA serves a more specialized func
tion in the CNS of mammals.

Indeed, it probably serves as

a direct mediator of chemical transmission.

The diverse

central functions are all very important determinants of
mammalian well-being, and the role of DA as a neurotrans
mitter in the CNS appears to be quite complex (Seeman et al^. ,
’78).

Functional abnormalities in DA systems are implicated

as being vitally important in determining such disease states
as Parkinsonism (Ehringer and Hornykiewicz, '60) and schizo
phrenia (Snyder,

*76).

These two disease states are believed

to be the result of diminished dopaminergic function in the
basal ganglia and pathologically increased activity in an
unidentified brain region, respectively.

The dopamine

hypothesis of schizophrenia is the most generally accepted
model of this disease.

Presumably, a population of neurons

exists that receives excessive dopaminergic input.

Neuro

leptics act as antipsychotic agents by blocking the postsynaptic receptors (Aghajanian and Bunney,
this superfluous DA exposure.

’74) experiencing

Additionally, dopaminergic

mechanisms are involved in such identified functions as
modulation of prolactin release (Caron et al., *78) and the
emetic response of the medullary chemoreceptor trigger zone.
Elucidation of the molecular mechanisms whereby DA produces
its effects may prove to be a valuable asset to clarifying
and understanding the role of DA in normal and pathological
states.
Prior to the early seventies, DA mechanisms were studied
exclusively in vivo.

Early conclusions regarding the role

of DA in the CNS were generally based upon whole animal
experiments in which behavioral parameters were observed.
These experiments were often difficult to interpret (Dankova
et a l ., *78) due in large extent to the fact that multiple
neuronal systems may potentially interact (Breese et a l . ,
*78).

The possibility of involvement of non-DA utilizing

neurons cannot be ruled o u t .
The questions of drug distribution and metabolism are

of real concern with in vivo models,

Compounding these

problems is the question of innate pharmacological specifi
city of the agents undergoing evaluation.

These potentially

confounding factors made in vivo models difficult to use in
investigations of DA molecular mechanisms.

Even so, in

vivo studies of the behavioral and neurophysiological effects
of dopaminergic systems (Van Rossum,

'78) have suggested

the existence of at least two types of receptors.
B.

In Vitro Models
The advent of in vitro models of dopaminergic systems

has allowed more discrete examination of the biochemical
pharmacological interactions between DA and its receptors.
While these in vitro models have refined the tests of DA
function, they have by no means produced explicit under
standing of these receptors.

The first model of a CNS

dopaminergic system identified and isolated was the
dopamine-stimulated adenylate cyclase (DA/AC) of the rat
neostriatum, a tissue rich in endogenous DA and adenylate
cyclase.

Kebabian et al.

( !72) reported that the enzymatic

activity of adenylate cyclase, catalysing the hydrolysis
and cyclization of adenosine 5'-triphosphate (ATP) to
adenosine 3',5'-cyclic monophosphate (cAMP), was increased
as a function of DA concentration.

The hypothesis was

presented by these authors that the DA-sensitive adenylate
cyclase was the putative DA receptor.

Subsequently, evidence

was presented that this DA-sensitive enzyme was the site of

action of antipsychotic drugs (Clement-Cormier et_ a l .t '74JL.
There is a significant discrepancy between the clinical
potency of one class of antipsychotic drugs and its ability
to inhibit DA/AC activity.

The butyrophenones, such as

haloperidol, are very potent in vivo, yet are weaker in
vitro inhibitors of DA/AC.

Since these early papers,

DA/AC has been detected in many brain regions responsive
to DA, with the notable exception of the anterior pituitary
gland (Schmidt and Hill,

*77).

The absence of demonstrable

DA/AC in anterior pituitary has also cast a degree of un
certainty upon the concept of this enzyme being the DA
receptor.

Furthermore, bromocryptine, a DA agonist in vivo,

is unable to stimulate DA/AC (Schwarcz et a l ., *78b).
A second type of in vitro DA receptor model developed
as a logical outgrowth of the DA/AC paradigm.

Obviously,

if DA stimulates the enzyme, it must first interact with it
in some fashion.

It was therefore reasonable to expect a

binding interaction, and experiments were undertaken to
identify this phenomenon (Burt e£ a l ., *75; Seeman e£ a l .,
'75).

Specific binding of radiolabeled DA and DA antagonists

was observed in preparations of mammalian caudate nucleus.
Following these initial reports, binding of radiolabeled
agonists (Creese ejt a l ., '75a; Seeman at a l ., '76b; Tittler,
et al., '77; Schwarcz et. al., *73b) and antagonists (Creese
et al., '77;Hyttel,

*78) was observed in a number of DA-

sensitive CNS tissues (Caron at al., '78; Pedigo et a l .,

*78).

The binding of these drugs was observed to be compe

titively inhibited by various unlabeled agonists and antago
nists.

All effective neuroleptics were shown to function

as antagonists in their ability to inhibit radioligand
binding.

Inhibition was observed to be proportional to

in vivo efficacy (Creese et al., '76).

The correlation

between in vitro binding inhibition and clinically admini
stered doses of antipsychotic drugs is extremely good.
This relationship also holds for the butyrophenones which,
as a group, departed from predicted behavior with DA/AC.
In addition, it was observed in very early experiments that
the dopamine receptor exhibited different properties, de
pending on whether an agonist or antagonist was being dis
placed (Creese et al., ’75b).
The fact that agonists were better at displacing agonists
compared to antagonists, while the converse was true for
antagonists, encouraged Creese et: al. ( ’75b) to posit a
two-state receptor model.

It was proposed that the DA

receptor existed in two rapidly interconvertible conforms-*
tions.

The presence of either an agonist or antagonist

was envisioned to induce the receptor to accomodate that
class of drug and therefore exchange more readily with a
similar class of competitor.

It was considered unlikely

that two distinct receptive structures were involved in
determining the difference between agonist and antagonist
displacement since' the total number and brain tissue dis

tribution (Leysen and Laduron,

r77) of these binding sites

were approximately equal.
C.

Problems In Receptor Models
It is readily apparent that, while these in vitro models

of dopaminergic systems have clarified questions of specific
drug effects, many mechanistic questions remain or, indeed,
have been produced.

Two obvious questions pertain to the

relationship between the receptors undergoing measure
ment in these assays.

First, what are the relationships be

tween DA/AC and the radioligand binding site and, secondly,
what is the exact relationship between the agonist and
antagonist receptive structures?

Answers to these questions

have proved to be elusive, but very recently some experi
mental evidence has been accummulating to support some
tentative conclusions (Kebabian and Caine,

*79).

Evidence regarding receptor non-identity or multiple
receptors has largely been anatomical, pharmacological, and
biochemical in nature.

It has been observed In ultracen

trifugation fractionation experiments that the subcellular
distribution of DA/AC and the antagonist binding site are
somewhat different in the rat striatum (Clement-Cormier and
George,

*78).

Another source of evidence suggesting recep

tor differences is that if cell bodies in the striatum are
chemically lesioned with kainic acid, DA/AC activity is
rapidly lost, while 507» of the total radio-antagonist
binding sites remain (Schwarcz et al,, '78a).

Kainic acid

is a glutamic acid analog that selectively destroys cell
soma while leaving cellular processes such as axons intact.
Residual binding after kainate lesioning (507o) is largely
eliminated following cortical ablation and this observation
is suggestive of a presynaptic binding site since the
cortex is a site of afferent innervation to the basal
ganglia.

A third line of evidence is that differences

are noted in pharmacological properties of the receptors
when the actions of dopaminergic ergots such as bromocryptine and lergotrile are examined.

These are potent

dopamine agonists at the anterior pituitary and compete with
specific agonist binding, yet they act as DA/AC antagonists
in the striatum (Kebabian and Caine,

*79).

After kainic

acid lesions in the striatum have been produced, sensiti
vity of radioligand binding to guanine triphosphate (GTP)
is lost (Creese et a l . , *79).

Since guanine nucleotides

supposedly regulate binding in association with adenylate
cyclase, the binding of radiolabeled agonists and antagonists
is believed to occur at one site coupled to adenylate
cyclase and one which is not.

In light of this evidence,

it appears that there are at least two forms of receptors
for dopamine.

Based upon these indirect observations, the

DA/AC receptor complex is apparently not identical to the
radioligand receptor.
The question pertaining to the nature of radioligand
binding sites persists.

What is the nature of the relation-

ship between the agonist and antagonist binding sites?
Analysis of this problem by the usual biological techniques
has proven to be difficult.

A mathematical analysis of

binding data has suggested that a model involving two
distinct sites may best fit observed effects (Beld et al^,
’78).

Indeed, Creese et al.

(_ '79), who originally proposed

the two-state model, now suggest that labeled agonists and
antagonists bind to distinct states of DA/AC dopamine
receptors.

This postulate is based on their observation

that agonist binding site drug-specificity resembles most
closely that of the DA/AC.
D.

Obj ectives
It appears that binding sites may be both coupled to

DA/AC and not coupled.

Regardless of the degree of indepen

dence between DA/AC and radioligand binding sites, there
remain at least two questions of potential importance.

Is

the receptive structure of DA/AC for dopamine and/or its
antagonists the same molecular entity as that involved in
agonist or antagonist binding sutdies?

Also, what is the

chemical relationship between the agonist and antagonist
binding sites?

Answers to these questions were the objec

tives of a series of experiments which will be described
in the following text.
An attempt to characterize the molecular properties of
the DA recognition site was undertaken through the use of
a specialized group of pharmacological probes.

It was

theorized that a competitive antagonist with some structural
elements common to the dopamine molecule would possess en
hanced selectivity in its dopaminergic effects.
evidence (Horn and Snyder,

There is

'71 ; Feinberg and Snyder,

*75)

that the prototype neuroleptic phenothiazine derivative,
chlorpromazine, does have a favored conformation that struc
turally mimics the dopamine molecule.

Many phenothiazine

derivatives with differing neuroleptic potencies have been
synthesized through the years and they all have structural
elements similar to DA.

Several structure-activity re

lationships for the antischizophrenic action of phenothiazine
derivatives have been well characterized (Gordon et a l .,
’63).

It is known that, for maximum activity, a three-

carbon chain between the 10-N of phenothiazine and its
terminal amino functionality is optimal.

If this aliphatic

moiety bears a side-chain or other functionality, activity
is generally reduced.

However, if a substituent is located

upon a carbon atom in this chain, an asymmetric center is
formed imparting to the molecule,

The effects of optical

isomerism within the 10-N substituent have not been analyzed
in any systematic or comprehensive fashion (Ferris at al.,
’76) .
Previous reports have suggested a stereospecific nature
of the DA receptor in vivo (Gordon et al., *63; Nielsen
et a l., *73; Humber et al_. , *75 ; Remy at al. , '77) as well
as in vitro (Burt et al., '76; Seeman et al., *76a).

These
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stereospecific effects of antagonists are seen with. both,
optical and geometric isomers,

tt is well known that opti

cal isomers have identical chemical properties (with achiral
moieties) whereas geometric iosmers do not.

Because optical

isomers exist in two discrete configurations, they can
influence receptors solely upon the basis of their fit to
the receptor (Text-Fig. 1).

Therefore, this class of com

pounds was envisioned as uniquely suitable for studying
the chemical properties of the DA. receptor.
Therefore, the experiments were undertaken to assess
specifically the stereospecificity of the DA recognition
site in various models of dopaminergic systems.

In vitro

models of DA/AC and 3Il-agonist and 3H-antagonist binding
were examined with selected optically active phenothiazine
derivatives.

Some of these optically active compounds

have been used clinically.

These useful drugs include

thioridazine (Mellaril), methotrimeprazine (Levoprome),
promethazine (Phenergan), and dioxopromethazine (Prothanon).
Promethazine and dioxopromethazine are not useful as neuro
leptics but do have antimetic and antihistaminic properties
due in part to their two-carbon aliphatic side chains
(Gordon et al., ’63).

Besides these clinically employed

drugs, there are many experimental optically active
phenothiazine derivatives which have not been approved for
use in humans (Usdin and Efron,

'72).

Nevertheless, these

compounds are of pharmacological interest and are suitable

11

S'

ti
t*
1

Text-Fig. 1. Enantioraers of methotrimeprazine. Each isomer
is shown in the favored conformation of pheno
thiazine neuroleptics with the dopamine molecule
(dashed figure) superimposed.
In the trans-grotamer conformation, dopamine exhibits several
structural elements in common with methotrimep
razine. It can be seen that the optical isomers
differ in their ability to approximate the
hydrophobic ethylene region in dopamine.
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for use In vitro.

One such optically active compound was

selected for use in these experiments because of its pur
ported unusual properties.

Usdin and Efron (. '72) classified

P-892 as a CNS excitant, an unusual property for a pheno
thiazine derivative.

Employing thioridazine, metho

trimeprazine, promethazine, dioxopromethazine, and P-892
isomers for investigations upon the DA receptor in vitro
was envisioned as providing a spectrum of affinities at the
recognition site with a wide range of chemical structures
(.Text-Fig. 2).

Methotrimeprazine and thioridazine both

possess the optimum three-carbon segment in their sidechain and as a group would be predictably potent
nists (Gordon et a l ., *63).

DA antago

In contrast, promethazine,

dioxopromethazine, and P-892 would be expected to function
poorly at displacing dopaminergic ligands.
E.

Hypothesis
If striatal DA/AC and the DA recognition sites were

identical, the relative difference in potency of isomeric
antagonists In the two systems would be the same.

One

would predict no difference in ratios of response between
the more active and less active enantiomers.

Furthermore,

if the previously observed differences between agonist and
antagonist binding displacement ( C r e e s e

e£ a l ., *75b) were

due to inherent differences in the nature of these drugs
rather than differentiation at two receptors, optical
isomeric effects again would be equal.

If phenothiazines
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Text-Fig. 2. Structures of optically active phenothiazine
derivatives used in receptor studies. Each
compound has a single asymetric carbon atom
which is designated with an asterisk.

cannot distinguish between receptors CKebabian and Caine,
'79) even in their isomeric forms, it would suggest that
the recognition sites are identical.
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II.

A.

EXPERIMENTAL

Materials
1.

Chemis try
All drugs used in the following experiments, whether

resolved { (+) or (-) > and/or racetnic (±), were originally
obtained directly from their respective pharmaceutical
manufacturer, with the exception of P-892.

The following

manufacturers provided the drugs ultimately utilized in
the pharmacological investigations:

Sandoz, (±)-thiorida

zine (Mellaril)j Rhone-Poulenc, (+) and (-)-methotrimeprazine; Wyeth,

(+) and (±)-promethazine (Phenergan); VEB

Arzneimittelwerk Dresden,

(+)-dioxopromethazine (Prothanon).

It was necessary to synthesize P-892 because its original
maker, Chemische Fabrik Promonta GMBH, was unable to provide
a sample of this phenothiazine derivative.

P-892 was

synthesized from phenothiazine and 1-methy1-2-piperidine
methanol, both obtained from Aldrich Chemicals.

The re

solving agent uniformly employed was di-£-toluyl-d-tartaric
acid, obtained from J.T. Baker Chemical Company.

All other

solvents and reagents utilized were commercially obtained
ACS reagent grade or USP.
Optical rotations were measured on a Rudolph polarimeter and/or a Zeiss polarimeter with a one decimeter micropolarimeter tube (capacity 0.55 ml).

Proton NMR spectra

were obtained from a C60H JEOL 60MHz instrument.

Mass
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spectra were obtained from direct sample introduction
into a Finnigan 4000 quadrupole instrument.

Those pheno

thiazine derivatives designated as photosensitive were
protected from light with actinic glassware whenever possible.
General reactions and procedures were performed with com
mercially available glassware.
2.

Pharmacology
a.

Binding Studies
Calf caudate nuclei were obtained from Valley-

dale Meat Packers, Bristol, VA,
obtained from commercial sources.

Radiolabeled drugs were
Tritiated DA, with

specific activities of 24.28 and 34.2 Ci/mmole, were pur
chased from New England Nuclear.

The specific label was

located on the 1-ethyl carbon atom to yield {ethyl-13H(N)} dopamine.

Tritiated spiroperidol (specific activity:

20 Ci/mmole) was purchased from Amersham Corporation.

This

compound was specifically labeled at the para position of
the H-phenyl group to yield { phenyl-4(N)-3H } spiroperidol.
Beta emissions were counted with the liquid scintilation
cocktail, Aquasol IX, from New England Nuclear.

Other

reagents were obtained from various commercial sources.
Specifically, pargyline HC1 and Tris buffer components
were purchased from Sigma Chemical Company.

Various salts

and other chemicals were of ACS reagent grade.

All

solutions were prepared using distilled water.

Butaclamol

HC1 salt was the generous gift of Ayerst Laboratories.
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The following specific items of apparatus were notably
important and therefore deserve attention.

Radioactivity

was monitored in all samples with a Beckman 9000 liquid
scintillation counter.

This unit is equipped with a micro

processor allowing data reduction under conditions of
uniform sample quenching.

Tissues were homogenized using

a Brinkman Polytron PT-10/35.

The homogenates were processed

in a Beckman L5-75B preparative ultracentrifuge equipped
with a Type 30 fixed angle rotor.

Millipore filter-holder

assemblies of both the glass frit and, later, stainless
steel support type were used.

These holders contained

Whatman GF/B filters (2,4 cm diameter) used throughout the
binding studies.
b.

Enzyme Studies
Striatal tissue used in the dopamine-stimulated

adenylate cyclase inhibition studies was obtained from rats.
Tissues were homogenized in a 30ml glass tissue grinding
tube with a motor driven teflon pestle.

Standard laboratory

apparatus and supplies were used whenever applicable in the
assay of adenyl cyclase activity.
Reagents and drugs used in the experiments were obtained
from commercial sources.

High purity adenosine 5'-tri

phosphate (ATP) from equine muscle, theophylline, Tris
buffer components, dopamine HC1, pargyline HC1, and ethyleneglycol bis^CS-amino-ethyl ether)-N-N'-tetraacetic acid (EGTA)
were all purchased from Sigma Chemical Company.

Other
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reagents required in the assay were ACS reagent grade
from various suppliers,

Cyclic 3 5 ' -^adenosine monophos

phate (cAMP) assays were performed with radioimmunoassay
(RIA) kits purchased from New England Nuclear.

This RIA

method is based upon the work of Steiner et a l , (.*72)
and differs from the method of Brown et al.
what other investigators have used.

(*72) which is

The RIA method is an

antibody saturation assay while that of Brown et al^
uses an endogenous binding protein.

(*72)

All centrifugation

steps were performed in a Beckman J 6 refrigerated centri
fuge.

Radioactivity from the 125I labeled cAMP tracer was

measured with a Beckman Gamma 7000 spectrometer.
All enzyme experiments were paired with modified 3H-DA
binding studies.

Materials used in these experiments

were those previously described in both the standard
binding studies and/or standard enzyme methods.
B.

Methods
1.

Chemistry
a.

Synthesis of Optically Active P-892
Technical grade (97%) phenothiazine was

purified by vacuum sublimation (Baker and Brickman,

'45).

The second required reactant, 2-chloromethyl piperidine,
was prepared in optically active form from racemic 1-methyl2-piperidine methanol as follows.

A 25ml aliquot of 1-

methyl-2-piperidine methanol was vacuum distilled (86° at
5 torr) to yield 17.5g of clear product.

This alcohol was
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resolved in a fashion analogous to that used upon 1-methyl3-piperidine methanol for the synthesis of optically active
thioridazine (Sandoz, Inc., *63).

The primary difference

in methodology was the necessary reduction to semi-micro
scale reaction.
Two grams (15mmol) of the primary alcohol dissolved in
7.3ml ethanol and 6.2g (ISmmol). di-£-toluyl-d-tartaric
acid in 23.3ml ethanol were mixed and allowed to stand at
room temperature.

Approximately 4g (7tranol) of (-) salt

precipitated out of solution.

This material was recrystal

lized from wet acetonitrile to yield 2.5g (Smmol) 0f pure
white crystals.

Basification with 5N NaOH and extraction

into ether yielded approximately 0.4g (3mmol) of (-)-lmethyl-2-piperidine methanol.

The original yellowish

mother liquor containing the (+) isomer salt was placed in
a freezer (approximately -20°C) overnight to facilitate
crystallization of remaining (-) salt.

When the resulting

supernate was filtered cold, then dried by rotating its
container in a hot (70°C) water bath with an applied vacuum
of about 18 torr (roto-evaporated)( 2 .6g (5mmol) of (+)
salt remained.

Alkalinization with 5N NaOH and extraction

into ether yielded approximately 0.5g (4mmol) free (+)-lmethyl-2-piperidine methanol.
The optically active alcohols were then Converted to
their respective alkyl chlorides by first forming HC1 salts
by bubbling anhydrous HC1 through solutions in dry chloroform.

20
The levorotatory salt was refluxed 3hr with. 0.7g (SiranolX
thionyl chloride, while the dextrorotatory salt was refluxed with 0.8g (6mmol).

When the reaction was terminated,

excess thionyl chloride and solvent were removed under
vacuum.

Basification with 5N NaOH and extraction into

ether of the isomers of 2-chloromethyl-l-methyl piperidineHC1 yielded 0.2g (Immol) of (-) base and 0.3g (2mmol) of
(+) base.

The low yields of 25 and 40% were primarily due

to losses in handling the serai-micro samples.
Using these resolved alkyl chlorides, synthesis of
optically active P-892 was readily accomplished.

Two

hundred mg (lmmol) of (-) alkyl chloride, 200mg Clmmol)
purified phenothiazine, and 50mg (.lmmol) sodium amide
were refluxed together for 3hr in dried m-xylene. The
solvent was roto-evaporated and product collected on a
micro cold-finger vacuum sublimation apparatus.
was virtually quantitative.

Synthesis of the dextrorota

tory compound was performed in like manner.
250mg (1.6mmol)

Yield

A mixture of

(+) alkyl chloride, 330 mg (l.Gmmol)

purified phenothiazine, and 66mg (1 .6mmol) sodium amide was
refluxed 3hr in dry m-xylene.

The product was extracted

with 0.1N HC1 and this aqueous phase was basified with
5N NaOH and counter-extracted with chloroform.

The organic

solvent was roto-evaporated to yield approximately 300mg
(lmmol) of product.
A routine check of purity by analytical thin-layer
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chromatography {silica gel G, with Skelly-Solv B (a light
hydrocarbon fraction)/isopropanol (.85:15 v/v)

as developing

solvent) was performed on the optical isomers of P-892.
They were observed to contain a second component.

This

material was produced in a side reaction not described in
references employing the same reaction scheme to produce
very similar compounds (Fujii et al,, ’58).

Apparently,

the side reaction occurred readily, as about 40% of the net
reaction product was comprised of this material.

Prepara

tive thin-layer chromatography with the same adsorbent
and solvent system produced an effective separation of
byproduct (I) from authentic P-892.

Compound I was sub

sequently shown to be a rearrangement compound with a sevenmembered ring system and the same molecular weight as P-892.
The identity of P-892 was verified by mass spectrometry,
NMR, and elemental analysis (Galbraith Laboratories, Inc.,
Knoxville, TN).

Small portions of both P-892 isomers in

their basic forms were subsequently converted to their re
spective hydrochloride salts.

Each base was first dissolved

in anhydrous ether and reacted with dry HC1 to yield a pre
cipitate of hydrochloride salt (approximately 5mg).
b.

Resolution of Dioxopromethazine
Resolution of this compound is based upon a

published technique (Wunderlich et al., f66),

The changes

incorporated were largely due to the necessity of working
with gram amounts rather than bulk quantities of the drug.
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Four grams of dioxopromethazine HC1 (Prothanon). ware con
verted to the base by dissolution into 50ml 1^0 and basification with. 11,4ml IN KOH.

The basic precipitate was then

extracted into a mixture of 80ml ether and 20ml dichloromethane.

The organic extract was filtered and dried to

yield approximately3.2g free base.

Two grams (finimol) of

this racemic base were dissolved in 66ml acetone and mixed
with 3.34g (8mmol) di-£-toluyl-d-tartaric acid in 24.2ml
methanol.

After 2hr stirring at room temperature, the pre

cipitate of (.-)-dioxopromethazine-£-toluyl-d-tartrate was
filtered, yielding approximately 2.4g (3mmol) of salt.

One

gram of this C~)-dioxopromethazine salt was subsequently
recrystallized from 400ml boiling methanol to yield 650mg
of enriched isomer,

A portion of this salt was then

basified, extracted, and roto-evaporated to yield (-)dioxopromethazine free base, from which approximately lOOmg
of hydrochloride salt was generated by bubbling dry HC1
gas through an anhydrous ether solution of the base.
The original mother liquor, remaining from the
crystallization of (-) salt, contained the (+) salt.

This

solution was roto-evaporated to yield (+)-dioxopromethazinedi-£-toluyl-d-tartrate. The basification and extraction of
this compound resulted in 0.9g (3mmol)
zine free base.

(+)-dioxoprometha

A portion of this base was reacted with

dry HC1 in anhydrous ether to yield approximately lOOmg
(+)-dioxopromethazine HC1 salt.

c.

Resolution of Thioridazine
This method was empirically developed, as the

author was unable to reproduce the cryptic method which
has previously been published CBourquin et a l . , ’58).
A 1.8g sample of racemic thioridazine hydrochloride was
converted to free base by reaction with 4,4ml IN KOH and
extracted into ether as the free base.

The organic phase

was roto-evaporated to yield thioridazine base as a
yellow, viscous oil.

Upon standing in vacuo for two weeks,

this oil solidified into yellow crystals.

To 0.9g (2.4mmol)

of the free base in 72ml cyclohexane and 20 ml chloroform
was added 0.98g (2.4mmol) di-£-toluyl-d-tartaric acid in
90ml ethyl acetate.

The final (+) salt fraction weighed

approximately 300mg in the form of pure white crystals.
The salt was converted to the hydrochloride salt by
bubbling dry HC1 through an anhydrous ether solution of
the base.
The original mother liquor was enriched in (-)-thioridazine-di-£-toluyl-d-tartrate. To remove the remaining (+)
salt, the solution was first roto-evaporated.

The dried

residue was mixed with 25ml cyclohexane and 150ml ethyl
acetate while heated and stirred.

Allowing this solution

to stand at room temperature for 24hr resulted in the
crystallization of additional (+) salt, rendering the
mother liquor further enriched in the (.-) isomeric salt.
This organic salt solution was then roto-evaporated and
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the resulting 0.5g of residue converted to the free base,
Basification with 5N KOH, extraction with- anhydrous ether,
and roto-evaporation of the organic phase produced a small
amount of (-)-thioridazine Base.

Again, a portion of this

base was converted to the hydrochloride with HC1 bubbled
through an ether solution.
d.

General Chemical Methods
Optical rotations were recorded from the free

base form of resolved phenothiazines. All resolved
phenothiazines were converted in part to the hydrochloride
salt form.

This was done largely to facilitate their

dissolution in aqueous media and to provide a uniform
acidic moiety within the pharmacological experiments.

The

purity of these hydrochloride salts was checked with
thin-layer chromatography (silica gel G; Skelly-Solv B/
isopropanol, 75:25 as developing solvent; iodine vapor
visualization).

This chromatographic procedure was intended

to detect drug decomposition products rather than exogenous
impurities.
2.

Pharmacology
a.

Binding Studies
Unless otherwise specified, all binding studies

were performed using methods developed in the laboratories
of Solomon H. Snyder at Johns Hopkins University (Burt
et al., '75; Creese et: al^., *77).
these experiments were as follows.

The major features of
Freshly slaughtered
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calves (cervical puncture) were quickly decapitated and
their brains removed after chopping away the skull's top,
Following transection of the hemispheres,

the anterior

caudate was exposed along the wall of the third ventricle.
The caudate was quickly excised and rapidly frozen with,
dry ice or liquid nitrogen.

Caudate nuclei from calf

brains stored 1 to 25 days at -50°C were homogenized with
the Polytron for 5 sec at a constant power setting of
approximately 50% in 30 volumes (w/v) ice cold 50mM
Tris HC1, pH 7.7 at 25°C (homogenizing buffer).

The

homogenate was centrifuged for 10 min at 5Q,000g in the
preparative ultracentrifuge at 4°C.

After the supernate

was discarded, the pellet was rehomogenized for 5 sec in
an additional 30 volumes of cold homogenizing buffer,
The homogenate was again centrifuged as before and the
supernate fluid discarded.

The final pellet was rehomo

genized as before but in ice cold 50mM Tris buffer, pH 7.1
at 37°C, containing IO ijM pargyline, 0.1% ascorbic acid,
120mM NaCl, 5mM KC1, lmM CaCl^ (Buffer A).
was then diluted

The homogenate

with additional cold Buffer A to make a

final 1:150 (w/v) caudate preparation, which was incubated
at 37°C for 10 min and then returned to an ice bath.
The assay system was comprised of the following compo
nents.

Each duplicate set of incubation tubes (borosili-

cate glass, 12x75mm) received 1.8ml caudate homogenate,
lOOpl test drug in varying concentrations in 0.1% ascorbic
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acid, or the vehicle along (control), and 100pi of radios
labeled agonist (3H-DA) or antagonist (spiroperidol, 3H-SP)
in 0.1% ascorbic acid, at appropriate concentrations.

Test

drug solutions were usually prepared on the day of the
experiment or, very rarely, stored frozen at -20°C, in 0.1%
ascorbic acid for less than two weeks.
were prepared on the day of use.

Radioligand solutions

Specific saturable radio

ligand binding was determined by measurement of binding in
the absence (total binding) and presence (non-specific
binding) of the stereospecific competitor,
at a concentration of lpM.

(+)-butaclamol,

The competition binding studies

were performed using an appropriate concentration range of
the optically active drug isomers and a radioligand con
centration determined to approach half-maximal receptor
saturation.
Each tube was incubated for 20 min at 37°C to attain
equilibrium between competitor and radioligand, then the
contents were rapidly vacuum filtered through pre-wetted
GF/B filters, followed by three 5ml washes of ice cold
homogenizing buffer.

Filters were transferred to glass

scintillation vials and allowed to dry overnight.

After

the addition of 10ml Aquasol, the vials were allowed to
stand overnight to extract trapped radioactivity into the
cocktail.

The vials were then counted for 6” emissions by

liquid scintillation spectrometry,
Scatchard analysis was performed on the saturation

27
binding data (Scatchard,

’49), using disintegrations per

minute (dpm) of the standards from the saturation studies
and the specific binding of radioligand,

For the teat

drug experiments, activity was automatically calculated
in terms of relative percent bound (%B), as compared to
total binding of radioligand used in the competition studies
as 100%B.

Zero %B was defined as that activity corresponding

to non-specific filter entrapment of radioligand from
assay tubes with Buffer A substituted for homogenate.

Per

cent bound data were then transformed into logit units
(Rodbard,

’74) using a programmed Monroe 1860 calculator.

Least square regression analysis between the transformed
logit data and their corresponding competitor concentration,
in logarithmic form, was calculated and plotted by a HewlettPackard HP 9825A desk-top computer.

Raw competition data

in counts per minute (cpm) were also subjected to computerized
analysis of variance (ANOVA),

The main effects analyzed

were Isomers and concentrations,with duplicate analyses
as a nested variable,
i.

3H-Dopamine Binding Experiments
Radiolabeled DA saturation studies were

performed using five concentrations of this ligand.
Concentrations examined were 2,5, 5, 10, 20, and 50nM
3H-DA,

All competition studies were performed with the

concentration of 3H-DA found by Burt et al. C'75) to
approach half maximal binding.

This concentration of 5nM
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3H-DA was utilized throughout the agonist experiments,
ii.

3H-Spiroperidol Binding Experiments
Radiolabeled SP saturation studies were

performed with five concentrations of this ligand.

The

concentrations examined were 0,15, 0.3, 0.5, 1.0, and
2.0nM 3H-SP.

All competition studies were performed with

the concentration of 3H-SP found by Creese et al. (’77)
to approach half maximal binding.

Throughout these

antagonist binding competition experiments, 0.15nM 3H-SP
was used.
b.

Dopamine-stimulated Adenyl Cyclase Experiments
Dopamine-sensitive cAMP production was assayed

essentially as originally described by Kebabian et a l .
C'72) with the modifications introduced by Clenent-Cortnier
et al.

(’75).

The experiments discussed below departed

from the original technique in the treatment of the
neostriatal tissues during and immediately after procure
ment.

Rather than obtaining the tissues in a cold room and

collecting the striata in a very complex nutrient buffer,
these tissues were collected as described by Miller et al.
(*74) and detailed below.
Rats were decapitated and their brains rapidly removed.
Striata were quickly dissected and placed in ice cold 2mM
Tris-maleate buffer, pH 7.4, containing 2mM EGTA (homo
genizing buffer).

Pooled striata (2 to 10 rats) were then

homogenized in 25 volumes of fresh cold homogenizing buffer
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by 15 pestle passes in the tissue grinding tube.

In one

experiment, frozen (18 hr) calf caudate tissue was substitued for fresh rat tissue.

Homogenization was sub

sequently carried out in all rat experiments..
The final assay mixture occupied a volume of 0.5ml.
This was comprised of 50pl test drugs at appropriate con
centrations in 0 .1% ascorbic acid or the vehicle alone
(0.001N HC1), 250pl buffer concentrate with additives,
and 50ul ATP.

The resulting standard assay mixture

contained these final concentrations of the following
substances:

Tris-maleate, 80.2mM; theophylline, lOmM;

MgSO^;2.0mM; EGTA,0.6m M ; ATP,0.5mM; DA, 40pM, pargyline,
10uM; ascorbic acid, 0 .1%; and test drugs at various con
centrations,

Reactions were performed In triplicate by

first adding homogenate to all solutions except ATP and
incubating on ice for 20 min.

The addition of ATP Initiated

the reaction, which was incubated at 30°C in a shaking
water bath for 2.5 min.

Termination of reaction was

effected by transferring the tubes to a boiling water bath
for 2.5 min.

The tubes were then centrifuged at 2000g for

10 min to precipitate the denatured protein.

Aliquots

of 100nl were taken from each tube and diluted

1:10 in

50 mM acetate buffer, pH 6.2, prior to analysis of cAMP of
lOOpl aliquots by RIA.

Radioimmunoassays were performed

exactly as specified in the instructions accompanying the
cAMP kit.

Data output from the Gamma 7000 was in the form

of %B radioactivity.

Comparison of these figures to a

standard curve prepared from known amounts of cAKP allowed
calculation of cAMP produced in the enzyme reaction under
the influence of the resolved phenothiazine, methotrimeprazine.

The amount of cAMP produced without stimulation

by 40yM DA was considered basal activity, corresponding
to 100% inhibition of stimulation.

In the presence of

40\jM DA and no competitor, maximum cAMP was produced
(0% inhibition).

The presence of various concentrations of

resolved methotrimeprazine yielded cAMP production
calculated in terms of % inhibition relative to the extremes
described above.
In some experiments, modified binding studies were
performed.

The tissue preparation and reaction milieu

was the same as that used in the enzyme assay except for
the following:

final volume, 2.0ml; no exogenous ATP was

added; 3H-DA concentrations used in these studies were
the same as those used in the binding studies previously
described.

In these modified binding studies, the attempt

was made to mimic conditions within the enzyme preparation.
Homogenization was performed with the glass tube/teflon
pestle tissue grinder, and preincubation was for 20 min
at 0°C.

Equilibrium of binding sites was allowed to occur

during a 20 min incubation at 37°C.

The receptor environ

ment was essentially like that used in DA/AC experiments:
Tris-maleate, 80.2mM; theophylline, 10mM; MgSO^, 2mM;

EGTA, 0.6niM; pargyline, 10uM; ascorbic acid, 0,1%; plus
test drugs at various concentrations.
c.

General Pharmacological Methods
Protein analyses' were performed on homogenates

using the method of Lowry et al.

(.'51).

All standards

(bovine serum albumin) were prepared in the same buffer
system used in preparing the tissue homogenate undergoing
protein analysis.
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A.

RESULTS

Chemistry
1.

Structural Verification of P-892
Various analytical techniques were employed to con

firm the identity of P-892.

Data from some physical methods

such as elemental analysis and mass spectrometry are pre
sented in Table 1.
in Text-Fig. 3,

The mass spectrum of P-892 is presented

The base peak of M/e 98 is consistent

with the predicted principal fragment of P-892.

This frag

ment apparently results from a-cleavage at both nitrogen
atoms.

The NMR spectrum of P-892 is shown in Text-Fig. 4.

Salient features of the NMR spectrum include:

characteris

tic aromatic proton signals at 6.7 to 7.45; an ABX complex
involving the methylene group bridging phenothiazine and
piperidine at 3.5 to 4.56; an ABX complex involving the
methylene group bridging phenothiazine and piperidine at
3.5 to 4.56, with coupling constants JAB=14.0

3 ^ = 6 . 86Hz,

J b x °6.36H z (Dr. B. Franzus, personal communication) and the
piperidyl methyl at 2.45.
2.

Verification of Isomeric Resolution
Optical activities of resolved phenothiazines are

given in Table 2.

These rotations are specifically for the

chemical form (base or salt) of the drug as noted in the
table.

These resolved phenothiazine derivatives were also

checked for chemical purity by thin-layer chromatography.
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Table I.
PHYSICAL PROPERTIES OF P-892

Elemental Analysis (HC1 salt)

Calculated

Observed1

% C

65.71

65.67

% H

6.62

6.87

% N

8.06

8.01

10.23

9.90

% Cl

Mass Spectrum (base)
Base peak M/e
Parent peak M/e

Predicted

Observed
98

98
310.47

Melting Point (IICl salt)

1 Galbraith Laboratories, Inc., Knoxville, TN

310

240-2°C

37921.
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Text-Fig. 3. Mass spectrum of purified P-892.
The parent
peak at 310 M/e and base peak at 98 M/e cor
respond to fragmentations predicted for P-892,

Text-Fig. 4. Nuclear magnetic resonance (NMR) spectrum
of purified P-892.

Table 2,
OPTICAL ACTIVITY OF RESOLVED PHENOTHIAZINES

Drug
Thioridazine base

Dioxopromethazine base

P-892 base

Specific Rotation
Observed

Isomer

Specific Rotation
Literature

(+)

{a}D° +33.0±11° Cc-l,EtOH) {«>d° +21,Q±2° (M.EtOH)1

(-)

{a>o° -37.0±3° (c=5,EtOH)

(+)

{a}£° -21,0+2° (M.EtOH) 1
20
{a}j)° + 6.2±l°Cc=10,Me2CO) {a}^ + 7.0°(c=10 ,MeCO)

C-)

{a)D° - 6.3±l°(c=20,Me2CO) {a}£° - 7,0°(c=5,Me2CO)

<+>

{a>D° +74.0+6°(c=l.3,EtOH)

C-)

{a>5“ -52.0+3°(c=l,EtOH)

20

Methotrimeprazine
20

tartrate

C+)

HCL

(->

ta}5" +16,9°(c=5,CHCI3 )
20
{a}D +11.5°(c =10,H20)

base

C->
(+)

{a>5“ -17.0O (c =5,CHC13)
25
+7.17°(c =1,H20)

Promethazine HC1

^ourquin et al., C'58)
2Wunderlich et al., O'66)
3Rhone-Poulenc, personal communcation

20

HJindholz, (*76)
5Wyeth, Inc., personal communication
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The thin-layer chromatogram of these resolved (and some
addition) phenothiazines is reproduced in Text-Fig, 5,

All

compounds chromatographed were in the form of hydro
chloride salts as this form was to be used in subsequent
pharmacological experiments.

Each compound was observed

to migrate as a single spot as the plates were developed.
B.

Pharmacology
1.

Binding Studies
a.

General Results
The isomeric competition data graphically re

presented are from those experiments with the highest
overall correlation coefficients among points within the
concentration series examined.

General agreement between

experiments with the same drug was observed, particularly
in regard to the ratio of IC^q’s of the isomers.

In all

experiments, cmp for duplicate samples in any group typi
cally varied 57o or less.

In the measurement of radio

activity by LSC, the amount of quenching in all samples
was constant.

This was evidenced by both uniform channel

ratios and H#'s (Long,

*77) for the samples.

Counting

efficiency was calculated to be 52.9±1.17a as determined by
the addition of 3H-toluene as internal standard.
b.

3H-Popamine
As described in the Methods section, saturation

data of specific dopamine receptors were calculated from
bound counts per minute from sets of samples without (total)
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Text-Fig, 5. Thin-layer chromatogram of phenothlazine
derivatives in HC1 salt form. The compounds
from which these samples were taken had been
exposed to various laboratory manipulations in
attempts to resolve the optical isomers. Only
one iodine-vapor staining spot is seen in each
sample of these test substances. Several of
these substances were subsequently employed in
pharmacological Investigations.
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and with, (non-specific) the addition of (+)-butaclaraol,
Within these sets of samples, the five concentration of
3H-DA added varied from 2.5 to 50 nM.

Total, non-specific,

and specific binding (.the difference between total and
non-specific) were all plotted on the same linear graph as
a function of 3H-DA concentration.

This generated typical

curves showing saturation of specific binding as an asympto
tic maximum is approached (Text-Fig. 6).

Scatchard analysis

of the saturation data typically revealed a dissociation constant (Kjj) of 1.98 x 10

_9

M and a maximal number of binding

sites CB_.nv.
lUaX) of 19.6 pmole/g wet weight tissue (Text-Fig. 7).
Competition studies performed with 5nM 3H-DA and various
concentrations of isomeric phenothiazine derivatives were
observed as per cent bound (%B) radioactivity.

Sigmoidal

curves were obtained by plotting %B 3H-DA vs. competitor
concentration on semilog graph paper.

Logit transformation

of %B data and replotting on logit-log scales produced
linear concentration curves.

These computer-displayed plots

are presented in figures 8 through 12,

The function best

fitting the linearized data in each plot revealed various
values for half-maximal inhibition of 3H-DA binding (XC^q)
by the respective isomers of phenothiazine derivatives.
These values represent the antilog of the X-intercept appear
ing on each plot and are
Table 3.

presented in tabular form in

The ratios of ICcr. values for each isomer pair
jU
are also shown in this table. This estimate of receptor
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Text-Fig. 6 , Example of a 3H-DA receptor saturation study.
The filled circles represent total binding of
radioligand at the designated concentrations.
Open circles represent non-specific binding
observed in the presence of lyM (+) butaclamol.
Specific binding, shown by the filled squares,
is the difference between total and non-specific
binding and is seen to plateau as it approaches
saturation.
Each point represents the mean
value of duplicate analyses.

41

0.010
CORR, COEFF, slope

0.008

-

0.9936

-5.04 x 108
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0.006
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3H-DA SPECIFIC BINDING: PMOLES / G
Text-Fig. 7. Scatchard plot of a 3H-DA saturation study.
The abscissa represents amounts of 3H-DA
specifically bound to striatal tissue, while
the ordinate is the ratio of specifically
bound over free 3H-DA. The dissociation con
stant (K_) is the negative reciprocal slope and
equals 2.0xl0-9M. Maximum 3H-DA binding sites
(B„ay ) are extrapolated from the X-intercept
antPapproach 20 pmol/g wet weight caudate
nucleus.
Each point is the mean from duplicate
analyses.
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Text-Fig. 8 . Computer-graphic plot of 3H-DA competition by
isomeric methotrimeprazine.
The abscissa is
log concentration of test drug and the ordinate
is logit transformed binding of 3H-DA. Cor
relation coefficients provide an estimate of
the ideality of observed competition effects.
The X-intercept represents the logarithm of the
ICjq value for each isomer.
Each point repre
sents the mean value of duplicate incubations.
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Text-Fig. 9. Computer-graphic plot of 3H-DA competition by
isomeric thioridazine(Mellaril). The abscissa
is log concentration of test drug and the ord
inate is logit transformed binding of 3H-DA.
Correlation coefficients provide an estimate of
the ideality of observed competition effects.
The X-intercept represents the logarithm of the
ICcq value for each isomer. Each point repre
sents the mean value of duplicate incubations.
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Text-Fig. 10. Computer-graphic plot of 3H-DA competition by
isomeric promethazine.
The abscissa is log
concentration of test drug and the ordinate is
logit transformed binding of 3H-DA.
Correla
tion coefficients provide an estimate of the
ideality of observed competition effects. The
X-intercept represents the logarithm of the
IC50 value for each isomer. Each point repre
sents the mean value of duplicate incubations.
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Text-Fig. 11. Computer-graphic plot of 3H-DA competition by
isomeric dioxopromethazine(Frothanon), The
abscissa is log concentration of test drug and
the ordinate is logit transformed binding of
3H-DA.
Correlation coefficients provide an
estimate of the ideality of observed competi
tion effects. The X-intercept represents the
logarithm of the ICcq value for each isomer.
Each point represents the mean value of dup
licate incubations.
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Text-Fig, 12. Computer-graphic plot of 3H-DA competition by
isomeric P-892.
The abscissa is log concen
tration of test drug and the ordinate is logit
transformed binding of 3H-DA. Correlation co
efficients provide an estimate of the ideality
of observed competition effects, The X-intercept represents the logarithm of the XC50 for
each isomer. Each point represents the mean
value of duplicate incubations.
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Tahle 3,

RADIOLABELED AGONIST BINDING INHIBITION

Drug

3 H-DA ICsu1
d

1

d/X

Methotrimeprazine

3.3x10"5

2.4x10" 6

Thioridazine

5.0x10"6

Promethazine

1 .0x10"

1 .8x 1 0 " 5
_ 52
7.1x 10

0.28*
2
1.41

Dioxopromethazine

4.6xl0-14

5. SxlO"1*

0.84

P-892

2 .6xl0"4

2 .8xlO“I+

0.93

13.75*

*p<0.05
1IC5o concentrations expressed In molarity (M).
2Values given are for di-promethazine.
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stereospecificity is marked with- an asterisk if the isomeric
effect was shown to be significant (p<0.05) by comparing the
F-values and degrees of freedom from ANOVA to the upper
significance limits of the F-distribution.

Under the

conditions employed in the competition studies, 3H-DA
total binding represented 1.4±0.2% (n=5) of the total
radioligand added to the assay mixture.

Specific binding

was 40.5±5.1% (n=4) of the total binding with 5nM 3H-DA.
c.

3H-Spiroperidol
As described in the Methods section, specific

saturation with spiroperidol was calculated from observed
cmp from sample sets prepared without (total) and with
(non-specific) the addition of (+)-butaclamol.

The

five concentrations of 3H-SP added to duplicate pairs in
each of these two sets varied from 0.15 to 2.0nM.

Total,

non-specific, and their difference (specific 3H-SP binding)
were plotted on a linear graph as a function of 3H-SP
concentration.

These graphs exhibited typical saturating

properties for specific binding, i.e. plateauing, as shown
in Text-Fig. 13.

Scatchard analysis of typical 3H-SP
- 11
saturation data revealed a K_ of 3.2 x 10
M and
D
max
of 28.7 pmoles/g wet weight of caudate nucleus tissue
(Text-Fig. 14).
Results of competition studies performed between
0.15nM 3H-SP and various concentrations of isomeric pheno
thiazine derivatives were observed as %B radioactivity.
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Text-Fig. 13. Example of 3H-SP receptor saturation study.
The filled circles represent total binding of
radioligand at the designated concentrations.
Open circles represent non-specific binding
observed in the presence of lpM (+) butac
lamol. Specific binding, shown by filled
squares, is the difference between total and
non-specific binding and is seen to plateau
as it approaches saturation. Each point rep
resents the mean values of duplicate analyses.

50
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SLOPE = -3,17 X 1 0 ^

0,8

Y INT. = 0.911
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SH-SP SPECIFIC BINDING: PMOLES / G WET WT.
Text-Fig. 14. Scatchard plot of 3H-SP saturation study.
The abscissa represents amounts of 3H-SP
bound to striatal tissue, while the ordinate
is the ratio of specifically bound over free
3H**SP, The dissociation constant ( K O is the
negative reciprocal of the slope, 3,2xlO"llM.
Maximum 3H-SP binding (B^x) sites are extra
polated from the X-intercept and approach 29
pmol/g wet weight caudate nucleus.
Each point
represents the mean from duplicate analyses.
t
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Linear curves were obtained by plotting logit transformed
%B data vs. log concentration of competitor.

The computer-

drawn plots are presented in Text-Fig. 15 through. 19. The
mathematical function best fitting the linearized data
points revealed various values for half-maximal inhibition
of 3H-SP binding by the respective phenothiazine isomers.
These values are the antilogs of the X-intercept appearing
on each plot and are presented in tabular form in Table 4.
The ratios of the IC^q values for each pair of antipodes
are also shown in this table.

This measure of stereo-

specificity is marked with an asterisk if the isomeric
effect was demonstrated to be significant by ANOVA
(p<0.05).

Under the conditions employed in these compe

tition studies, total 3H-SP binding represented 42.8+1.6%
(n=4) of all the radioligand in the assay mixture.
Specific binding amounted to 89.4±0.6% (n=4) of the total
3H-SP binding.
2.

Enzyme Studies
Adenylate cyclase activity in rat striatal homo-

genates was observed to be stimulated by the addition of
exogenous DA.

Addition of 40yM DA enhanced cAMP produc

tion by 40.4+8.5% (n=3) under conditions employed in the
enzyme assay.

In two experiments studying the influence

of (+) and (-) methotrimeprazine upon DA/AC, the mean
stimulation of enzyme activity by DA was somewhat smaller:
29.2%.

Mean basal activity (non-stimulated activity is
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Text-Fig. 15. Computer-graphic plot of 3H-SP competition by
isomeric methotrimeprazine.
The abscissa is
log concentration of test drug and the ordinate
is transformed binding of 3H-SF.
Correlation
coefficients provide an estimate of the ideal
ity of observed competition effects. The X-intercept represents the logarithm of the TCjq
value for each isomer.
Each point represents
the mean value of duplicate incubations.
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Text-Fig. 16. Computer-graphic plot of 3H-SP competition by
isomeric thioridazine(Mellaril). The abscissa
is log concentration of test drug and the ord
inate is logit transformed binding of 3H-SP.
Correlation coefficients provide an estimate
of the ideality of observed competition
effects.
The X-intercept represents the loga
rithm of the IC50 value for each isomer.
Each
point represents the mean value of duplicate
determinations.
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Text-Fig.

17. Computer-graphic plot of 3H-SP competition by
isomeric promethazine.
The abscissa is log
concentration of test drug and the ordinate is
logit transformed binding of 3H-SP.
Correla
tion coefficients provide an estimate of the
ideality of observed competition effects.
The
X-intercept represents the logarithm of the
IC50 value for each isomer.
Each point repre
sents the mean value of duplicate incubations.
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Text-Fig, 18. Computer-graphic plot of 3H-SP competition by
isomeric dioxopromethazine(Frothanon). The
abscissa is log concentration of test drug and
the ordinate is logit transformed binding of
3H-SF.
Correlation coefficients provide an
estimate of tje ideality of observed competi
tion effects. The X-intercept represents the
logarithm of the ICcq value for each isomer.
Each point represents the mean value of dupli
cate incubations.
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Text-Fig. 19. Computer-graphic plot of 3H-SF competition by
isomeric P-892.
The abscissa is log concentra
tion of test drug and the ordinate is logit
transformed binding of 3H-SP.
Correlation co
efficients provide an estimate of the ideality
of observed effects. The X-intercept repre
sents the logarithm of the IC«jq value for each
isomer.
Each point represents the mean value
of duplicate incubations.
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Table 4.

RADIOLABELED ANTAGONIST BINDING INHIBITION

Drug

3H-SP I C *
50
d
1

d/1

7.8 X i o “ 6

9.5 X 10‘8

Thioridazine

4.3 X i o " 6

8.8 X

Promethazine

2.0 X i o ‘ 5

5.5 X i o “ 5 2

0 .3 6 * 2

Dioxopromethazine

7.1 X 10" 5

2.6 X 10”11

0.27*

P-892

6.3 X 10'5

6.3 X

10'5

1 .00*

td
1
O
H

Methotrimeprazine

*p<0.05
1IC^q concentrations expressed in molarity (M).
2Values given are for dl-promethazine.

82.10*
0.49*
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defined as 100% inhibition of stimulation) of 48 pmol/mg/rain
was increased to 62 pmol/mg/min by 40uM DA C0% inhibition)..
Any inhibition of stimulated DA/AC activity by the test
substances was expected to fall within the ranges of 0-100%.
A plot of mean % inhibition of DA/AC as a function of
methotrimeprazine isomer concentrations is shown in TextFig. 20.

Standard errors, not shown in this figure ranged

from 8 to 23%, resulting in no significant (p<0.05, t
dependent) isomer effect upon DA/AC by this compound.

The

fact that no isomer effect was observed in this in vitro
model left unanswered the question of whether the model was
functioning as it was expected to.

Demonstration of a

concentration-dependent inhibition of activity (Miller
et a l ., ’74b) would suggest that the assay was properly
sensitive to a neuroleptic.

Since there was no isomer effect

observed, the enantiomers could be considered as a group:
a racemate.

Comparison of the grouped extremes of concen_ti

tration CIO

_6

to 5 x 10

M) does reveal a significant

(p<0.05, t dependent) concentration effect for this compound
considered as a racemate.

The net XC^q for (+)-methotrime_8
prazine is estimated to be approximately 7 x 10 M.
Attempts at pairing binding studies with the DA/AC
measurements failed.

Binding studies using 3H-DA in the

same homogenate medium in which DA/AC is assayed were totally
unsuccessful.

It was impossible to demonstrate specific

3H-DA binding in either calf or rat caudate homogenates
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Text-Fig. 20. Inhibition of dopamine-stimulated adenyl cyc
lase activity by methotrimeprazine optical
isomers.
Each point represents the mean value
of triplicate incubations.
Standard errors
(not shown) ranged from 8 to 23% inhibition,
resulting in no significant isomeric effect
upon enzyme activity with methotrimeprazine.
Overall IC^q value for (+) methotrimeprazine
in the enzyme system is approximately 7x10 M.

60
prepared in the same fashion as those for DA/AC,

Since

specific 3H-DA binding did not occur, it was impossible to
study competition effects with test isomeric phenothiazine
derivatives.
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IV.

A.

DISCUSSION

Chemistry
The objectives of the various chemical procedures under

taken in this project were twofold.

First, a relatively

novel compound, F-892, was to be synthesized in its optically
active Isomeric forms.

Secondly, racemic thioridazine and

dioxopromethazine were to be resolved into their dextroro
tatory and levorotatory isomers.

These goals were ultimate

ly achieved.
On the basis of the qualitative organic analyses per
formed upon P-892, it appears correct to state that this
compound has indeed been synthesized,

Observed specific

rotations indicate that it has also been resolved into
optical isomers.

Since there is no reference in the chemical

literature to this compound, there are no means of comparing
it to accepted criteria of chemical or optical purity.
Chemical purity Is apparently quite good, as only a single
substance is observed in analytical thin-layer chromato
graphy and NMR spectroscopy (Warren et: a i . , '66).
addition,

In

the mass spectral and elemental analysis data do

not suggest the presence of any contaminating material.
The question of the extent of optical purity in the resolved
P-892 isomers remains unanswered.

The difference between

the observed rotations of the two isomers (Table 2) suggests
that the C+) isomer is better resolved.

It may be possible
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that errors in the relatively subjective measure of specific
rotation (obtained with the very small amounts of these
isomers- available) may have contributed to this difference,
Nevertheless, the large specific rotations observed do
indicate attainment of resolution (Table 2).
The other compounds were also appreciably resolved into
their antipodes.

Comparison of observed rotations to the

literature values for thioridazine and dioxopromethazine
enantiomers indicates that they approach or exceed published
values (Table 2).

Because semi-micro scale quantities of

these compounds were used in making the subjective rotation
measurements, departures from published values are probably
due to observational errors.

Verification and objective

quantification of the degree of optical resolution effected
with these drugs would require an additional analytical
procedure.

Nuclear magnetic resonance spectroscopy employing

a chiral shift reagent could provide an estimate of optical
purity in these samples (Kime and Sievers,

'77).

As the

equipment has not been available for performing this ancillary
analysis on milligram size samples, optical rotation data
must suffice for demonstrating isomeric resolution.

Based

upon rotation data, then, one may conclude that all drugs
used in the pharmacological studies were resolved to a
relatively high degree of optical purity.
Chemical purity of thioridazine HC1 and dioxoprometha
zine HC1 was also readily demonstrated.

After the many
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manipulations required to separate their isomers, contamina
tion might have been anticipated.

Analytical thin-layer

chromatography demonstrated that only one pure substance
was contained in each sample of the resolved isomers.

The

other compounds shown in Text-Fig. 5 were initially planned
for pharmacological evaluation but were subsequently omitted.
Their deletion was due to the fact that neither oxomemazine
HC1 nor I-HC1 (P-892 rearrangement compound) were, in fact,
successfully resolved into optical isomers.

Resolution

of racemic bases into enantiomers is a completely empirical
technique.

Methods which are successful with one compound

are not, as a rule, successful with another.

Due to the

difficulty of working with only one resolving agent and
milligram quantities of oxomemazine and compound I, attempts
at resolution failed after several weeks of work and further
attempts were abandoned.
B.

Pharmacology
1.

Binding Studies
a.

General Considerations
i.

Saturation Studies
A basic supposition in these experiments was

that radioligand binding was indeed specific and saturable
and that the number of these binding sites was approximately
equal for both agonists and antagonists.

Evidence for this

conclusion had been presented earlier by Burt et al.

C'75)

and Creese et al^ C'77) for 3H-DA and 3H-SP respectively.
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While a report by Briley and Langer C'78) indicated two
binding sites for 3H-SP in rat caudate nucleus, this
apparently is not the situation in calf caudate ( C r e e s e
et al., ’77).

The data obtained from the saturation

studies do indicate that the numbers of binding sites for
3H-DA and 3H-SP are quite similar (Text-Fig. 7 and 14).
Furthermore, the B
values are in essential agreement
max
with those reported in the literature (Burt et a l ., *75;
Creese et al., '77) for the respective radioligands.

The

use of 3H-SP as a model labeled antagonist had been found
to be highly advantageous (Leysen et a l ., ’78) for in vitro
binding studies.

This situation appeared to prevail in

these experiments as well.

Specific binding curves for

each ligand were observed to be similar in all experiments
employing the standard conditions described in the Methods
section and used in the competition studies.

It was

concluded, therefore, that the two binding assays were
functioning optimally.

Furthermore,

it was concluded that

competition studies would render data relevant to previous
observations and consistent with postulates formulated
upon these in vitro models.
ii.

Competition Studies
It is clear that optical isomers of some

phenothiazine derivatives do have differential effects
upon both agonist and antagonist dopaminergic radioligand
binding.

The observed effects of these enantiomers, in
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competition with labeled DA and SP, suggest several
properties attributable to their receptors.

Two trends

are discernable in the overall data from binding competition
experiments,

The first of these is that the difference

between isomeric effects (ratio of (+) and (r) ^ 5 0
values) is, in general, greater for those compounds with the
smaller IC^q's.

This observation is in keeping with

Pfieffer's postulate ('56); the more potent a competitor
is at displacing the radioligand, the greater is its
ratio of isomeric effects.

A logical refinement of this

postulate suggests an even more broad-based conclusion.
As Ariens et al.(r79) explain, if the asymmetric center
of a functionality does markedly influence pharmacological
effects, that functionality is then a critical element
in receptor interaction.

As previously mentioned, the

chemical nature of the 10-N substituent (Text-Fig. 2) has
been strongly implicated in phenothiazine antipsychotic
effects (Gordon et al., '63; Fenner,

’70).

The in vitro

observations described in this text do substantiate the
concept of direct involvement of the 10-N-alkyl func
tionality in phenothiazine/receptor interactions.

There

are two interesting aspects of this phenomenon apparent
from the binding data.

Both methotrimeprazine and thiori

dazine possess the optimum antischizophrenic three-carbon
chain between the 10-N and the terminal tertiary amino
group.

Methotrimeprazine contains its asymmetric carbon
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at the 2 position, while thioridazine's is at the 3
position and is distinguished by less rotational freedom
due to its location in the piperidine heterocyclic
ring structure

(Text-Fig.

2).

In the 2 position, a greater

isomeric effect is observed than in the 3 position.

Further

more, an inversion of optical activity corresponding to the
isomer with greater displacing ability (and presumably
greater receptor affinity) is seen as the asymmetric carbon
is moved to the 3 position.

More generally, this is the

observed situation when the asymmetric center is next to
the terminal amino group.

This is the case in thioridazine

competition with 3H-DA and 3H-SP, while it is seen only in
3H-SP displacement by promethazine and dioxopromethazine.
This will be elaborated upon in a later section.
This brings us to the second major fact obtained from
the binding studies as a group.

In keeping with previous

reports (Creese et a l ., ’75b), antagonists (such as the
phenothiazine derivatives studied in these experiments)
displace antagonists (3H-SP) better than they displace
agonists (3H-DA).
smaller

This is evidenced by the correspondingly

value of the more potent isomer (or equipotent

isomer) for 3H-SP competition compared to 3H-DA.

This

observation was a keystone of the two-state receptor theory.
These experimental data support this theory on the basis
of similar observations, yet surpass the previous indirect
evidence,

There is a large difference observed in stereo-
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specificity (ratios of 1C,-q values between (+) and X~)
isomers) between 3H-DA and 3R-SP binding.

Differences

are seen in comparison of isomeric stereospecificity for
all drugs tested except P-892, a compound with no discernable CNS effects (Hieschulz et a l . , '56, ’59).

This ob

servation is compatible with both the two-state or the twodistinct receptor models.

A two-state receptor could

theoretically change conformation to such an extent that
stereospecific recognition of a test antagonist would be
markedly altered.

Two distinct receptors would, by de

finition, possess different stereospecificities.

The data

obtained from the binding competition studies are clearly
incompatible with the notion that 3H-DA and 3H-SP bind to
an identical recognition site.

This conclusion is also

supported by a recent thermodynamics analysis of agonist
and antagonist binding (Lew and Goldstein,
Ariens et al.

’79).

C'79) have proposed an interesting model

of recognition sites on receptors.

Their concept of a

receptor is based upon physico-chemical observations and
theories which include similar phenomena as those observed
in these experiments.

As a rule, antagonists are larger

and more hydrophobic than agonists.

Hydrophilic agonists

are envisioned as interacting with relatively hydrophilic
regions on a membrane such as an externally oriented protein
region.

The interface between this protein and surrounding

lipid molecules would comprise an accessory binding site
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that would accomodate antagonists.

This interface would

be a highly ordered set of atoms, almost crystalline in
nature.

If a hydrophobic region of an antagonist inter

acted with a lipid/protein interface, a high degree of
stereospecificity might be expected,

A situation such as

this is dramatically evident in 3H-DA and 3H-SP binding
competition with (+) and (-)-methotrimeprazine.

It can

be seen from Tables 3 and 4 that the stereospecificity of
the 3H-SP receptor is roughly six times that of the 3H-DA
receptor.
b.

3H-Dopamine Binding Competition
The salient point in the experiments with

3H-DA displacement is that an isomeric effect is seen only
with methotrimeprazine and thioridazine.

These are the

two drugs in this study with clinically useful neuroleptic
actions.

In contrast, promethazine, dioxopromethazine, and

P-892 are devoid of clinically useful antipsychotic effects,
and all fail to exhibit a stereospecific interaction with
the 3H-DA recognition site (Table 3).

These compounds

are not well discriminated by the receptor, as millimolar
concentrations are required to displace half of 3H-DA
binding.

The recognition site for 3H-DA is only able to

discriminate between configurations of compounds with the
highest affinities and intrinsic neuroleptic actions.
c,

3H-Spiroperidol Binding Competition
The recognition site for 3H-SP is capable of

69
differentiating between configurations of many phenothiazine derivatives (Table 4).

Since this site has a high

order of stereospecificity which exceeds the boundary of
neuroleptic effects, the "antagonistic site” may be pharma
cologically differentiable from the "neuroleptic site".
While promethazine is not a clinically useful neuroleptic and
has no stereospecific effect on 3H-DA binding, its (+)
isomer is approximately twice as effective as the racemate
in displacing 3H-SP.

Interestingly, promethazine is

capable of inducing extrapyramidal side effects which are
also general characteristics of phenothiazine neuroleptics
(Wade,

*77).

This suggests, perhaps, a potentiality for

discriminating between neuroleptic effects and "antagonist
site" effects (e.g. Parkinsonism) in drug design.
A comment is in order concerning the isomeric effects
of P-892.

While ANOVA suggests a significant differential

effect upon 3H-SP binding with C+) and (-)-P-892 at the
95% confidence level, this is not realistic.

The signifi

cant difference between these two isomers is solely a
product of the exceptional reproducibility within duplicate
samples at each concentration of these competitors.

Repro

ducibility was generally better in 3H-SP experiments than
in those with 3H-DA, but with P-892, variation between
duplicates was on the order of 1%.

The more realistic

check upon isomeric effects, the ratio of (+) to (-)
values, demonstrates the actual equivalence of these two
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configurations of P-892,

A ratio equal to or near a value

of 1.0 indicates equipotence in pharmacological action,
d.

Isomeric Drug Effects
It is apparent from the experimental data

that neuroleptic effects of some clinically employed agents
are influenced by their optical isomers.
one such drug.

Thioridazine is

If this medication were administered in the

dextrorotatory form, optimal antischizophrenic effects
might be obtained at lower overall dosage.

When one

examines a plot of in vivo neuroleptic dose vs in vitro
response by Seeman et al.

(.'76a), it is apparent that thiori

dazine departs the most from an otherwise excellent corre
lation.

Racemic thioridazine is also the only optically

active agent included on this graph.

Since only a portion

of the racemic dose is actually effective in controlling
schizophrenia, a plot of the active (+) isomer dose vs.
its effect should more closely correspond to the general
correlation seen withotherneuroleptics of all classes.
The data suggests that (-)-methotrimeprazine may be
a highly potent neuroleptic.

While this compound is used in

Europe, it is not approved for use as a neuroleptic in
the United States.

Currently,

(-)-methotrimeprazine is

indicated for use in this country only as an analgesic.
The relatively high doses used for analgesia produce marked
hypotension as an adverse effect.

With the apparently low

doses of this drug necessary to ameliorate schizophrenic

71
symptoms, this side effect may be negligible.
2.

Enzyme Assay
The effects of methotrimeprazine upon DA/AC were

in marked contrast to those in the binding studies.

Where

(.-)-methotrimeprazine was much more effective at inhibiting
both 3H-DA and 3H-SP binding in the calf caudate preparation
(Tables 3 and 4), no significant isomeric effect was seen
in rat DA/AC.

The DA/AC model of dopaminergic systems

appears to lack stereospecificity at the receptor recogni
tion site for this neuroleptic. If one assumes that the
intrinsic nature of rat and calf radioligand binding sites
are the same (.Burt et al. , '75) and that both in vitro
systems approximate physiological!! reality, then it is possi
ble to conclude that the recognition sites for DA/AC and
3H-DA binding are different.
This conclusion must be considered in light of data from
the ancillary binding studies which were coupled to the
DA/AC experiments.

It was impossible to demonstrate

specific saturable binding of 3H-DA within the conditions
used for the enzyme assay.

This situation prevailed with

both fresh rat caudate homogenates and frozen calf caudate
nucleus homogenates.

The fact that the type and molarity

of the buffer system required for maximal enzyme activity
was quite different from that employed in the binding
studies may be postulated to alter the conformation of the
receptor site.

This is a commonly recognized phenomenon
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in enzymological studies and there is evidence that the
DA receptor is proteinaceous in nature (Breton eh a l . , *77) ,
Overall, it is difficult to reconcile the differences in
methodology between the DA/AC and radioligand binding in
vitro models.

Methodological differences make conclusions

regarding the identity of the receptors in question diffi
cult to defend on a logical basis.

Postulates regarding

the relationship between DA/AC and radioligand binding sites
as presented by Creese et al.
highly speculative.

C’79) must be considered as

The fact that drug specificity at

radio-agonist binding sites more closely resembles DA/AC
drug sensitivity than does radio-antagonist binding specifi
city may actually be an experimental artifact.
3.

Further Research
a.

Binding Studies
The observation that (-)-methotrimeprazine and

(+)-thioridazine are the more potent isomers in displacing
both 3H-DA and 3H-SF is an interesting point.

As noted

previously, the salient structural differences between these
drugs is the location of the asymmetric carbon in either
a 2-propyl or 2-piperidyl position, respectively.

The

difference in rotation of the most active agent itself is
of interest, but the absolute magniturde of differences in
isomeric effects (stereospecificity) is of note, too.

It

is possible that the distance between the terminal amino
function and the asymmetric center is a critical parameter

73
influencing drug/receptor interaction.

If this is the

prevailing situation, the magnitude of isomeric differences
could serve as an index of significance for particular
orientations (both distance and angle) of substituents added
to phenothiazine (or other heterocyclic systems) in design
ing neuroleptic drugs.

Asymmetry may serve as a high reso

lution probe of geometric interaction of various neuroleptic
compounds with their target receptors.

If many of the op

tically active phenothiazines available could be obtained
in their enantiomeric forms, more refined studies of
receptor topology has been presented previously (Miller
et al., '74a; Clement-Cormier et al., *79) with much more
restrictive pharmacological probes.

Actually analyzing recep

tor topography could have implications for designing more
efficacious drugs.

It might ultimately be possible to

tailor an antagonist for the particular target receptor that
antidopaminergic side effects such as Parkinsonism would be
removed from the spectrum of neuroleptic effects (Kukla
et al., ’79).
It must be remembered that these in vitro binding studies
have largely focused upon the basal ganglia.

This is most

likely due to the fact that there is rich dopaminergic
innervation in the striatum.

It is highly probably that

the disruption In dopaminergic function presumed to cause
schizophrenic manifestations is located in other brain
regions.

A recent report by Bird et al.

(*79) suggests that
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the nucleus accumbens may actually be the site of biochemi
cal alteration in schizophrenia.

It may be a reasonable

extension of in vitro studies to examine dopaminergic
receptor characteristics in other brain areas such as the
nucleus accumbens.
b.

Enzyme Studies
The studies with DA/AC reported in this text

must be considered preliminary.

Additional experiments are

required to characterize more precisely the influence of
enantiomers upon this in vitro dopaminergic system.

A

recent report (Clement-Cormier ejt a l ,, *79) dealing with the
optical isomeric effects of alkaloids containing a rigid
DA pharmacophore upon DA/AC does indicate a differential
inhibition by this class of drugs.
Regardless of the ultimate degree in technical resolu
tion of the enantiomeric influences upon DA/AC, a frustra
ting question will persist.

Since the in vitro models of

3H-DA binding and DA/AC are incompatible and each subjects
the receptors to different environments, a novel approach
must be taken before these models can be appropriately
compared.

Until such a technological break-through is

obtained, the relationship between these two systems will
remain an enigma.
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